If you are found to be eligible to take part in this study, you will receive tremelimumab by vein over 60 minutes on Day 1 of Cycles 1-4. You will not receive tremelimumab after Cycle 4. You will also receive durvalumab by vein over about 60 minutes on Day 1 of Cycles 1-13.